{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:37:10Z","timestamp":1753889830158,"version":"3.41.2"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec><jats:title>Aim &amp; Objective:<\/jats:title><jats:p>The objective of this retrospective study was to investigate the efficacy of adding remogliflozin to current insulin glargine plus two oral drug i.e. metformin and teneligliptin therapy in poorly controlled Indian type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods:<\/jats:title><jats:p>173 study participants were initially selected from patient database who continued on their insulin glargine or received an increased dose of insulin glargine along with other OHA based therapy (Group A) and 187 were selected who had received remogliflozin (100 mg BD) (Group B) in addition to insulin glargine along with other OHA based therapy. Glycated haemoglobin (HbA1c), total daily insulin dose, body weight, and the number of hypoglycemic events were recorded at weeks 0, 12 and 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result:<\/jats:title><jats:p>During the study, mean values of HbA1c, FBG and P2BG were significantly reduced in both groups. Insulin requirements decreased from 45.8 \u00b1 16.7 IU\/day to 38.5 \u00b1 13.5 IU\/day (P &lt; 0.001) and at week 24 even further decreased to 29.5 \u00b1 14.5 IU\/Day . Twenty three patients in group B were able to cease insulin treatment altogether after 24 week treatment. It has been observed to attain tight blood glucose control we need to increase insulin dose in group A from 45.5 \u00b1 16.5 IU\/Day to 51.5 \u00b1 14.5 at week 12 (P&lt;0.01) and which further increased to 53.8 \u00b1 12.8 IU\/Day at week 24 (P&lt;0.01). Adding remogliflozin showed significant effect on blood pressure (P &lt; 0.001) and weight reduction (P &lt; 0.001). It has been observed that 38% patients has achieves targeted HbA1c (\u22647%) in group B where it was 22% in group A.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Results demonstrate that in uncontrolled T2DM patients remogliflozin 100 mg BD can successfully lay a foundation for prolonged good glycemic control. Early addition of remogliflozin with insulin glargine plus OHAs may be an alternative compare to intensive up titration of insulin daily dose in people with uncontrolled T2DM. Clinical Trial Registration Number: A 2358<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573399817666201222102520","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T04:07:43Z","timestamp":1608696463000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents"],"prefix":"10.2174","volume":"17","author":[{"given":"Anand","family":"Shankar","sequence":"first","affiliation":[{"name":"Shankar Diabetes Care and Research Center, Patna,India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","volume":"28","author":"Ohkubo Y.","year":"1995","unstructured":"Ohkubo Y.; Kishikawa H.; Araki E.; Miyata T.; Isami S.; Motoyoshi S.; Kojima Y.; Furuyoshi N.; Shichiri M.; Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995,28(2),103-117","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"Turner R.C.","year":"1999","unstructured":"Turner R.C.; Cull C.A.; Frighi V.; Holman R.R.; Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA UK Prospective Diabetes Study (UKPDS) Group1999,281(21),2005-2012","journal-title":"JAMA"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1111\/j.1742-1241.2007.01598.x","volume":"61","author":"Hammer H.","year":"2007","unstructured":"Hammer H.; Klinge A.; Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007,61(12),2009-2018","journal-title":"Int J Clin Pract"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","volume":"371","author":"Bretzel R.G.","year":"2008","unstructured":"Bretzel R.G.; Nuber U.; Landgraf W.; Owens D.R.; Bradley C.; Linn T.; Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008,371(9618),1073-1084","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1463-1326.2008.00980.x","volume":"11","author":"Blickl\u00e9 J-F.","year":"2009","unstructured":"Blickl\u00e9 J-F.; Hancu N.; Piletic M.; Profozic V.; Shestakova M.; Dain M.P.; Jacqueminet S.; Grimaldi A.; Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009,11(4),379-386","journal-title":"Diabetes Obes Metab"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4158\/1934-2403-25.6.622","volume":"25","author":"Tamez-P\u00e9rez H.E.","year":"2019","unstructured":"Tamez-P\u00e9rez H.E.; Gonzalez-Guajardo E.E.; Tamez-Pe\u00f1a A.L.; Consensus statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. Endocr Pract 2019,25(6),622","journal-title":"Endocr Pract"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"Davies M.J.","year":"2018","unstructured":"Davies M.J.; D\u2019Alessio D.A.; Fradkin J.; Kernan W.N.; Mathieu C.; Mingrone G.; Rossing P.; Tsapas A.; Wexler D.J.; Buse J.B.; Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018,61(12),2461-2498","journal-title":"Diabetologia"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Wiviott S.D.","year":"2019","unstructured":"Wiviott S.D.; Raz I.; Bonaca M.P.; Mosenzon O.; Kato E.T.; Cahn A.; Silverman M.G.; Zelniker T.A.; Kuder J.F.; Murphy S.A.; Bhatt D.L.; Leiter L.A.; McGuire D.K.; Wilding J.P.H.; Ruff C.T.; Gause-Nilsson I.A.M.; Fredriksson M.; Johansson P.A.; Langkilde A.M.; Sabatine M.S.; Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med DECLARE\u2013TIMI 58 Investigators2019,380(4),347-357","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med EMPA-REG OUTCOME Investigators2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"Wanner Ch.","year":"2016","unstructured":"Wanner Ch.; Inzucchi S.E.; Zinman B.; Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016,375(18),1801-1802","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40265-019-01150-9","volume":"79","author":"Markham A.","year":"2019","unstructured":"Markham A.; RemogliflozinEtabonate: First global approval. Drugs 2019,79(10),1157-1161","journal-title":"Drugs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40265-020-01285-0","volume":"80","author":"Dharmalingam M.","year":"2020","unstructured":"Dharmalingam M.; Aravind S.R.; Thacker H.; Paramesh S.; Mohan B.; Chawla M.; Asirvatham A.; Goyal R.; Shembalkar J.; Balamurugan R.; Kadam P.; Alva H.; Kodgule R.; Tandon M.; Vaidyanathan S.; Pendse A.; Gaikwad R.; Katare S.; Suryawanshi S.; Barkate H.; Efficacy and safety of RemogliflozinEtabonate, a new sodium glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled trial. Drugs 2020,80(6),587-600","journal-title":"Drugs"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1177\/0145721705285638","volume":"32","author":"Meece J.","year":"2006","unstructured":"Meece J.; Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006,32(1)(Suppl.),9S-18S","journal-title":"Diabetes Educ"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/sj.ijo.0802173","volume":"26","author":"Korytkowski M.","year":"2002","unstructured":"Korytkowski M.; When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002,26(Suppl. 3),S18-S24","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref=15","first-page":"e418","volume":"56","author":"Harris S.B.","year":"2010","unstructured":"Harris S.B.; Kapor J.; Lank C.N.; Willan A.R.; Houston T.; Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010,56(12),e418-e424","journal-title":"Can Fam Physician"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.2337\/dc10-2434","volume":"34","author":"Rubin D.J.","year":"2011","unstructured":"Rubin D.J.; Rybin D.; Doros G.; McDonnell M.E.; Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care 2011,34(8),1723-1728","journal-title":"Diabetes Care"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3810\/pgm.2014.10.2824","volume":"126","author":"Shaefer C.F.","year":"2014","unstructured":"Shaefer C.F.; Reid T.S.; Dailey G.; Mabrey M.E.; Vlajnic A.; Stuhr A.; Stewart J.; Zhou R.; Weight change in patients with type 2 diabetes starting basal insulin therapy: Correlates and impact on outcomes. Postgrad Med 2014,126(6),93-105","journal-title":"Postgrad Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4S51","DOI":"10.1016\/S1262-3636(05)88268-0","volume":"31","author":"Larger E.","year":"2005","unstructured":"Larger E.; Weight gain and insulin treatment. Diabetes Metab 2005,31(4 part 2),4S51-6","journal-title":"Diabetes Metab"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.2337\/diacare.28.12.2948","volume":"28","author":"Zammitt N.N.","year":"2005","unstructured":"Zammitt N.N.; Frier B.M.; Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005,28(12),2948-2961","journal-title":"Diabetes Care"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2337\/diacare.28.2.260","volume":"28","author":"Raskin P.","year":"2005","unstructured":"Raskin P.; Allen E.; Hollander P.; Lewin A.; Gabbay R.A.; Hu P.; Bode B.; Garber A.; Initiating insulin therapy in type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care INITIATE Study Group2005,28(2),260-265","journal-title":"Diabetes Care"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1464-5491.2005.01475.x","volume":"22","author":"Douek I.F.","year":"2005","unstructured":"Douek I.F.; Allen S.E.; Ewings P.; Gale E.A.; Bingley P.J.; Continuing metformin when starting insulin in patients with Type 2 diabetes: A double-blind randomized placebo- controlled trial. Diabet Med Metformin Trial Group2005,22(5),634-640","journal-title":"Diabet Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"Wilding J.P.","year":"2012","unstructured":"Wilding J.P.; Woo V.; Soler N.G.; Pahor A.; Sugg J.; Rohwedder K.; Parikh S.; Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med Dapagliflozin 006 Study Group2012,156(6),405-415","journal-title":"Ann Intern Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"Rosenstock J.","year":"2015","unstructured":"Rosenstock J.; Jelaska A.; Zeller C.; Kim G.; Broedl U.C.; Woerle H.J.; Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab EMPA-REG BASALTM trial investigators2015,17(10),936-948","journal-title":"Diabetes Obes Metab"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1463-1326.2011.01412.x","volume":"13","author":"Fonseca V.","year":"2011","unstructured":"Fonseca V.; Gill J.; Zhou R.; Leahy J.; An analysis of early insulin glargine added to metformin with or without sulfonylurea: Impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011,13(9),814-822","journal-title":"Diabetes Obes Metab"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1007\/s00125-007-0633-0","volume":"50","author":"Fonseca V.","year":"2007","unstructured":"Fonseca V.; Schweizer A.; Albrecht D.; Baron M.A.; Chang I.; Dejager S.; Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007,50(6),1148-1155","journal-title":"Diabetologia"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1742-1241.2002.tb11251.x","volume":"56","author":"Rosenstock J.","year":"2002","unstructured":"Rosenstock J.; Einhorn D.; Hershon K.; Glazer N.B.; Yu S.; Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract Pioglitazone 014 Study Group2002,56(4),251-257","journal-title":"Int J Clin Pract"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.2337\/dc12-2718","volume":"36","author":"Yki-J\u00e4rvinen H.","year":"2013","unstructured":"Yki-J\u00e4rvinen H.; Rosenstock J.; Dur\u00e1n-Garcia S.; Pinnetti S.; Bhattacharya S.; Thiemann S.; Patel S.; Woerle H.J.; Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: A \u226552-week randomized, double-blind study. Diabetes Care 2013,36(12),3875-3881","journal-title":"Diabetes Care"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1463-1326.2011.01543.x","volume":"14","author":"Pontiroli A.E.","year":"2012","unstructured":"Pontiroli A.E.; Miele L.; Morabito A.; Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and meta-analysis. Diabetes Obes Metab 2012,14(5),433-446","journal-title":"Diabetes Obes Metab"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/dom.12393","volume":"17","author":"Sykes A.P.","year":"2015","unstructured":"Sykes A.P.; Kemp G.L.; Dobbins R.; O\u2019Connor-Semmes R.; Almond S.R.; Wilkison W.O.; Walker S.; Kler L.; Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 2015,17(1),98-101","journal-title":"Diabetes Obes Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.2147\/DDDT.S221093","volume":"14","author":"Mohan V.","year":"2020","unstructured":"Mohan V.; Mithal A.; Joshi S.R.; Aravind S.R.; Chowdhury S.; Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020,14,2487-2501","journal-title":"Drug Des Devel Ther"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399817666201222102520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/189341\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399817666201222102520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:52:34Z","timestamp":1697421154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/189341\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399817666201222102520","relation":{},"ISSN":["1573-3998"],"issn-type":[{"type":"print","value":"1573-3998"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e122120189341"}}